Epigenetics-targeted drugs: current paradigms and future challenges
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Epigenetics governs a chromatin state regulatory system through five key mechanisms: DNA modification, histone modification, RNA modification, chromatin remodeling, and non-coding RNA regulation. These mechanisms and their associated enzymes convey genetic information independently of DNA base sequences, playing essential roles in organismal development and homeostasis. Conversely, disruptions in epigenetic landscapes critically influence the pathogenesis of various human diseases. This understanding has laid a robust theoretical groundwork for developing drugs that target epigenetics-modifying enzymes in pathological conditions. Over the past two decades, a growing array of small molecule drugs targeting epigenetic enzymes such as DNA methyltransferase, histone deacetylase, isocitrate dehydrogenase, and enhancer of zeste homolog 2, have been thoroughly investigated and implemented as therapeutic options, particularly in oncology. Additionally, numerous epigenetics-targeted drugs are undergoing clinical trials, offering promising prospects for clinical benefits. This review delineates the roles of epigenetics in physiological and pathological contexts and underscores pioneering studies on the discovery and clinical implementation of epigenetics-targeted drugs. These include inhibitors, agonists, degraders, and multitarget agents, aiming to identify practical challenges and promising avenues for future research. Ultimately, this review aims to deepen the understanding of epigenetics-oriented therapeutic strategies and their further application in clinical settings.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Epigenetics-targeted drugs: current paradigms and future challenges
- Date Crossref
- 26/11/2024
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
China Medical University Department of Obstetrics and Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
West China Medical Center of Sichuan University Department of Gynecology and Obstetrics pays non établi dans la noticeÉtablissement de santé
-
Shenyang 242 Hospital pays non établi dans la noticeÉtablissement de santé
-
Shenyang Maternity and Child Health Hospital pays non établi dans la noticeÉtablissement de santé
-
Liaoning Cancer Hospital & Institute Department of General Internal Medicine VIP Ward pays non établi dans la noticeÉtablissement de santé
-
National Health and Family Planning Commission pays non établi dans la noticeOrganisme public
-
Sichuan University pays non établi dans la noticeUniversité ou école supérieure
-
West China Second University Hospital of Sichuan University pays non établi dans la noticeÉtablissement de santé
-
West China School of Basic Medical Sciences & Forensic Medicine Department of Forensic Genetics pays non établi dans la noticeUniversité ou école supérieure
-
Key Laboratory of Reproductive Dysfunction Diseases and Fertility Remodeling of Liaoning Province pays non établi dans la noticeStructure de recherche
Department of Obstetrics and Gynecology — China Medical University, Department of Gynecology and Obstetrics — West China Medical Center of Sichuan University et Shenyang 242 Hospital, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.